Amended and Restated License Agreement by and between bluebird bio, Inc. and Celgene Corporation and Celgene European Investment Company LLCLicense Agreement • November 1st, 2017 • Bluebird Bio, Inc. • Biological products, (no disgnostic substances) • New York
Amendment No. 2 to Amended and Restated Master Collaboration AgreementAmendment No. 2 to Amended and Restated Master Collaboration Agreement • November 1st, 2017 • Bluebird Bio, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 2 to Amended and Restated Master Collaboration Agreement (this “Amendment No. 2”) is made as of September 28, 2017 (“Amendment No. 2 Effective Date”), by and between bluebird bio, Inc. (“Bluebird”), a Delaware corporation, and Celgene Corporation, a Delaware corporation (“Celgene Corp.”), and Celgene European Investment Company LLC (“Celgene Europe”), a Delaware limited liability company (Celgene Europe and Celgene Corp., together, “Celgene”). Each of Bluebird and Celgene may be referred to herein as a “Party” or together as the “Parties”. Reference is hereby made to that certain Amended and Restated Master Collaboration Agreement, by and between Bluebird, Celgene Corp. and Celgene Europe, dated June 3, 2015, as amended (the “Agreement”). Capitalized terms used but not otherwise defined herein shall have the meanings given to such terms in the Agreement.
INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT...License Agreement • November 1st, 2017 • Bluebird Bio, Inc. • Biological products, (no disgnostic substances)
Reference is hereby made to that certain License Agreement dated August 13, 2014 (the “License Agreement”) by and between Biogen MA Inc., a corporation organized and existing under the laws of Massachusetts, having its principal place of business at 250 Binney Street, Cambridge, Massachusetts 02142, USA (“Biogen”) and bluebird bio, Inc., a corporation organized and existing under the laws of Delaware, having its principal place of business at 50 Second Street, Third Floor, Cambridge, MA 02141, USA (“Bluebird”). Any capitalized terms not defined herein shall have the meaning set forth in the License Agreement.
